are there less side effects with tirzepatide Multiple of The promise of tirzepatide: A

CSII use is associated with small improvements in HbA 1c and fewer hypoglycaemic events, suggesting that CSII can be considered in people living with type 2 diabetes treated with multiple daily insulin injections and able to manage the device [71]

Symptoms like difficulty breathing, swelling of the face or throat, and severe dizziness require immediate medical attention

Pre-existing medical conditions can impact B12 absorption and utilization

(2018, October 11)

While preclinical data is promising, its important to recognize that neither peptide is FDA-approved for human therapeutic use, and most evidence is derived from animal or laboratory studies

Bhatt DL, Szarek M, Steg PG, et al